Salt restriction is an effective strategy to attenuate or prevent VEGF inhibitor-induced toxicity, primarily the rise in blood pressure.
ID
Bron
Verkorte titel
Aandoening
Hypertension; VEGF inhibitor-induced toxicity; renal carcinoma; thyroid carcinoma; hepatocellular carcinoma; gastrointestinal stroma cell tumor
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
mean difference in blood pressure rise between the treatment cycle with and the treatment cycle without salt restriction.
Achtergrond van het onderzoek
Rationale: Growth and metastatic spread of a malignant tumor requires the formation of new blood vessels. Recent therapies target this mechanism by inhibiting vascular endothelial growth factor (VEGF)-signalling. Although this is an effective anticancer treatment, many patients develop cardiovascular side effects such as hypertension and kidney disease, frequently requiring dose reduction and/or early termination of treatment while still effective. Therefore, strategies to prevent VEGF inhibitor-induced toxicity are urgently needed.
In animal studies, VEGF inhibitor-induced hypertension is salt-sensitive. In this study, we want to study salt restriction in cancer patients treated with VEGF inhibitors sunitinib and regorafenib as a strategy to attenuate or prevent VEGF inhibitor-induced toxicity, primarily the rise in blood pressure.
Objective: To prospectively study the effect of salt restriction on the rise in blood pressure in response to anti-cancer treatment with the VEGF inhibitor sunitinib and regorafenib.
Study design: This is a single centre prospective open-label intervention study to compare a treatment cycle using salt restriction with the previous treatment cycle without salt restriction.
Study population: Patients treated with sunitinib or regorafenib according to standard of care, using a standard dosing regimen.
Intervention: A salt restricted diet (<4 grams/day) will be started during the off-treatment period under guidance of a specialized dietititan. Salt-less bread will be provided. The whole period of salt restriction will take four (regorafenib) or five (sunitinib) weeks.
Main study parameters/endpoints: Primary endpoint: mean difference in blood pressure rise between the treatment cycle with and the treatment cycle without salt restriction.
Secondary endpoints: effects of salt restriction on rise in endothelin-1, proteinuria as marker for nephropathy and pharmacokinetics of sunitinib and regorafenib; if an effect on blood pressure is shown, further analyses of effects on renal transporter proteins will be performed to explain the mechanism of salt sensitivity.
Doel van het onderzoek
Salt restriction is an effective strategy to attenuate or prevent VEGF inhibitor-induced toxicity, primarily the rise in blood pressure.
Onderzoeksopzet
The last endpoint is at the end of treatment cycle with regorafenib or sunitinib in which the salt restriction was applied
Onderzoeksproduct en/of interventie
Salt restricted (<4g/day) diet
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
• Registered indication for sunitinib or regorafenib in the standard treatment regime 4 weeks treatment and 2 weeks off (sunitinib) or 3 weeks on/1 week off (regorafenib).
• Blood pressure well controlled at baseline (<135/85 mmHg day average at 24h ABPM or <140/90 mmHg office)
• Written informant consent
• Age ≥ 18 years
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
• Not providing informed consent or not capable of giving informed consent
• Using antihypertensive drugs other than a calcium channel blocker at baseline
• Weight loss of 10% or more in the previous six months indicating undernutrition
• Insufficient understanding of Dutch language
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL7340 |
NTR-old | NTR7556 |
Ander register | NL66666.078.18 : MEC 2018-155 |